WANBURY240.65

Wanbury Limited

· Pharma & Health
₹ CrorePeersAHCLANUHPHRBAJAJHCARETHEMISMEDZIMLABLINCOLNSIGACHIVALIANTLABMcap ₹789 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
Last 12M
30/06/2025
Inventory Days (DIO)31.1745.4649.4949.49
Receivable Days (DSO)49.6656.7169.5069.50
Payable Days (DPO)210.46205.39181.87176.42
Cash Conversion Cycle (days)-129.63-103.22-62.88-57.43
Working Capital Turnover-2.52-10.5031.8433.45
Asset Turnover1.641.681.451.45
Cash Conversion (CFO/Net Income)-1.900.070.850.85
CFO/EBITDA0.850.060.340.34
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY25 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.